β‘ This is your brand? Claim your page FREE and bring it to life on AI search.
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. TOLREMO therapeutics: Stopping Non-genetic Cancer Drug Resistance as it Emerges just got measured.
4/10 means TOLREMO therapeutics: Stopping Non-genetic Cancer Drug Resistance as it Emerges is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. By stopping cancer drug resistance as it emerges, we aim to surmount a universal challenge for current and future targeted therapies for lasting patient benefit.
Industry: Technology
tolremo.com2
Structured Data
5
Content Structure
5
Entity Clarity
4
E-E-A-T Signals
7
Technical AEO
3
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
Tech buyers are the most research-intensive shoppers on the internet.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for TOLREMO therapeutics: Stopping Non-genetic Cancer Drug Resistance as it Emerges.
Scored by Engagemii on July 3, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/tolremo
Cite this score: Engagemii (2026). "AEO Score for TOLREMO therapeutics: Stopping Non-genetic Cancer Drug Resistance as it Emerges." Retrieved from https://engagemii.com/aeo/brands/tolremo
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - AI Brand Discovery and AEO Platform